

# Protein content of the *Oenococcus oeni* extracellular vesicles-enriched fraction



Instituto de Ciencias de la Vid y del Vino


Miguel Mejías Ortiz, Ana Mencher, Pilar Morales, Jordi Tronchoni, Ramon Gonzalez

Instituto de Ciencias de la Vid y el Vino (ICVV-CSIC-UR-GR)

miguel.mejias@icvv.es



## MALOLACTIC FERMENTATION AND EV'S




- Malolactic fermentation (MLF) is almost essential for most red wines and some white wines.
- MLF is performed by lactic acid bacteria. *Oenococcus oeni* is the main responsible of spontaneous MLF. For this reason, commercially available starters for MLF usually contain *O. oeni* strains.
- EV's are non-replicative particles delimited by a lipid bilayer and released by cells. They are involved in intra- and interspecific interactions and can carry diverse components inside them.


To understand the interactions between microbial starters, extracellular vesicles (EV) have been hypothesized as part of the interaction mechanisms.

## METHODOLOGY

### Extracellular vesicles purification and concentration




### Characterization and proteome analysis




Created in BioRender.com bio

## RESULTS




Cellular component GO term of the most abundant proteins present in EV-enriched fraction.



GeneSCF graph representing significant KEGG categories from the *O. oeni* EV-enriched proteome. "MP share" stands for the percentage of the corresponding metabolic pathway covered by the proteins included in each category.

MP share  
 ○ 15 %  
 ○ 20 %  
 ○ 25 %  
 ○ 30 %  
 ○ 35 %



Number of proteins shared by *O. oeni* and *L. plantarum* EV-enriched fractions.

## CONCLUSIONS

- *O. oeni* EV's are similar to other bacterial EV's described before.
- Ribosomal and integral membrane proteins are the most abundant protein categories in the EV-enriched fraction.
- These features are also found in other bacterial and eukariotic species.

## REFERENCES

- Betteridge, A., Grbin, P., & Jiranek, V. (2015). *Trends in Biotechnology*, 33 (9).
- Jahromi, L. P., & Fuhrmann, G. (2021). *Advanced Drug Delivery Reviews*, 173.

## FUNDING

Grant PID2019-105159RB-I00 and BES-2016-077557 funded by:



Grant PRE2020-093420 funded by:

